FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 337:809-815 September 18, 1997 Number 12 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Clozapine, a relatively expensive antipsychotic drug, is widely used to treat patients with refractory schizophrenia. It has a low incidence of extrapyramidal side effects but may cause agranulocytosis. There have been no long-term assessments of its effect on symptoms, social functioning, and the use and cost of health care.

Methods We conducted a randomized, one-year, double-blind comparative study of clozapine (in 205 patients) and haloperidol (in 218 patients) at 15 Veterans Affairs medical centers. All participants had refractory schizophrenia and had been hospitalized for the disease for 30 to 364 days in the previous year. All patients received case-management and social-rehabilitation services, as clinically indicated.

Results In the clozapine group, 117 patients (57 percent) continued their assigned treatment for the entire year, as compared with 61 (28 percent) of the patients in the haloperidol group (P<0.001). As judged according to the Positive and Negative Syndrome Scale of Schizophrenia, patients in the clozapine group had 5.4 percent lower symptom levels than those in the haloperidol group at all follow-up evaluations (mean score, 79.1 vs. 83.6; P = 0.02). The differences on a quality-of-life scale were not significant in the intention-to-treat analysis, but they were significant among patients who did not cross over to the other treatment (P = 0.003). Over a one-year period, patients assigned to clozapine had fewer mean days of hospitalization for psychiatric reasons than patients assigned to haloperidol (143.8 vs. 168.1 days, P = 0.03) and used more outpatient services (133.6 vs. 97.9 units of service, P = 0.03). The total per capita costs to society were high — $58,151 in the clozapine group and $60,885 in the haloperidol group (P = 0.41). The per capita costs of antipsychotic drugs were $3,199 in the clozapine group and $367 in the haloperidol group (P<0.001). Patients assigned to clozapine had less tardive dyskinesia and fewer extrapyramidal side effects. Agranulocytosis developed in three patients in the clozapine group; all recovered fully.

Conclusions For patients with refractory schizophrenia and high levels of hospital use, clozapine was somewhat more effective than haloperidol and had fewer side effects and similar overall costs.

Source Information

From the Veterans Affairs Connecticut Healthcare System, West Haven, and the Department of Psychiatry, Yale School of Medicine, New Haven, Conn. (R.R., J.C., L.F., D.C.); the Center for Cooperative Studies in Health Services, Hines Veterans Affairs Medical Center, Hines, Ill. (W.X., J.T., W.H.); and the Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M. (C.F.).

Address reprint requests to Dr. Rosenheck at the Northeast Program Evaluation Center (182), VA Connecticut Healthcare System, 950 Campbell Ave., West Haven, CT 06516.

Full Text of this Article

Related Letters:

Review of Living Downstream
Frumkin H., Berke J. H., Schwartz R. S.
Extract | Full Text  
N Engl J Med 1998; 338:268-269, Jan 22, 1998. Correspondence

This article has been cited by other articles:

• Patnaik, M., Renda, M. J., Athanasiou, M. C., Reed, C. R. (2008). The Role of Pharmacogenetics in Treating Central Nervous System Disorders. Exp. Biol. Med. 233: 1504-1509 [Abstract] [Full Text]  
• Paciullo, C. A. (2008). Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 65: 1825-1829 [Abstract] [Full Text]  
• Barbui, C., Signoretti, A., Mule, S., Boso, M., Cipriani, A. (2008). Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?. Schizophr Bull 0: sbn030v1-sbn030 [Abstract] [Full Text]  
• Leucht, S., Heres, S., Hamann, J., Kane, J. M. (2008). Methodological Issues in Current Antipsychotic Drug Trials. Schizophr Bull 34: 275-285 [Abstract] [Full Text]  
• Rabinowitz, J., Levine, S. Z., Barkai, O., Davidov, O. (2008). Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design Features. Schizophr Bull 0: sbn005v1-sbn005 [Abstract] [Full Text]  
• Kreyenbuhl, J., Marcus, S. C., West, J. C., Wilk, J., Olfson, M. (2008). Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia. Focus 6: 212-220 [Abstract] [Full Text]  
• Mitchell, A. J., Selmes, T. (2007). Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv. Psychiatr. Treat. 13: 336-346 [Abstract] [Full Text]  
• Rosenheck, R. A. (2007). Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br. J. Psychiatry 191: 238-245 [Abstract] [Full Text]  
• Kreyenbuhl, J., Marcus, S. C., West, J. C., Wilk, J., Olfson, M. (2007). Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia. Psychiatr. Serv. 58: 983-990 [Abstract] [Full Text]  
• (2007). References. APPI Online CME 2007: 2-2 [Full Text]  
• Swartz, M. S., Perkins, D. O., Stroup, T. S., Davis, S. M., Capuano, G., Rosenheck, R. A., Reimherr, F., McGee, M. F., Keefe, R. S.E., McEvoy, J. P., Hsiao, J. K., Lieberman, J. A., for the CATIE Investigators, (2007). Effects of Antipsychotic Medications on Psychosocial Functioning in Patients With Chronic Schizophrenia: Findings From the NIMH CATIE Study. Am. J. Psychiatry 164: 428-436 [Abstract] [Full Text]  
• Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S.E., Swartz, M., Perkins, D. O., Hsiao, J. K., Lieberman, J. (2006). Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. Am. J. Psychiatry 163: 2080-2089 [Abstract] [Full Text]  
• Burton, S. (2006). Symptom domains of schizophrenia: the role of atypical antipsychotic agents.. J Psychopharmacol 20: 6-19 [Abstract]  
• Chue, P. (2006). The relationship between patient satisfaction and treatment outcomes in schizophrenia.. J Psychopharmacol 20: 38-56 [Abstract]  
• Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., Jones, P. B. (2006). Randomized Controlled Trial of Effect of Prescription of Clozapine Versus Other Second-Generation Antipsychotic Drugs in Resistant Schizophrenia. Schizophr Bull 32: 715-723 [Abstract] [Full Text]  
• Lieberman, J. A. (2006). Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).. Arch Gen Psychiatry 63: 1069-1072 [Full Text]  
• Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., Lewis, S. W. (2006). Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).. Arch Gen Psychiatry 63: 1079-1087 [Abstract] [Full Text]  
• Lambert, B. L., Cunningham, F. E., Miller, D. R., Dalack, G. W., Hur, K. (2006). Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia. Am J Epidemiol 164: 672-681 [Abstract] [Full Text]  
• McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S.E., Davis, C. E., Severe, J., Hsiao, J. K., for the CATIE Investigators, (2006). Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. Am. J. Psychiatry 163: 600-610 [Abstract] [Full Text]  
• Honer, W. G., Thornton, A. E., Chen, E. Y.H., Chan, R. C.K., Wong, J. O.Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., Williams, R., MacEwan, G. W., Wasan, K., Procyshyn, R., the Clozapine and Risperidone Enhancement (CARE) S, (2006). Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. NEJM 354: 472-482 [Abstract] [Full Text]  
• Heres, S., Davis, J., Maino, K., Jetzinger, E., Kissling, W., Leucht, S. (2006). Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics. Am. J. Psychiatry 163: 185-194 [Abstract] [Full Text]  
• Greenberg, G. A., Rosenheck, R. A. (2005). Special Section on the GAF: Using the GAF as a National Mental Health Outcome Measure in the Department of Veterans Affairs. Psychiatr. Serv. 56: 420-426 [Abstract] [Full Text]  
• Greenberg, G. A., Rosenheck, R. A. (2005). Special Section on the GAF: Continuity of Care and Clinical Outcomes in a National Health System. Psychiatr. Serv. 56: 427-433 [Abstract] [Full Text]  
• Rosenheck, R. A. (2005). Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator. Psychiatr. Serv. 56: 85-92 [Full Text]  
• Buchanan, R. W., Ball, M. P., Weiner, E., Kirkpatrick, B., Gold, J. M., McMahon, R. P., Carpenter, W. T. Jr. (2005). Olanzapine Treatment of Residual Positive and Negative Symptoms. Am. J. Psychiatry 162: 124-129 [Abstract] [Full Text]  
• Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., Shaughnessy, R. A. (2005). Clozapine Augmented With Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Am. J. Psychiatry 162: 130-136 [Abstract] [Full Text]  
• Sernyak, M. J., Rosenheck, R. (2004). Economic Grand Rounds: Systemwide Costs Associated With Second-Generation Antipsychotics in the Treatment of Schizophrenia. Psychiatr. Serv. 55: 1361-1362 [Full Text]  
• Kho, K. H., Moncrieff, J. (2004). Author's reply. Br. J. Psychiatry 184: 539-540 [Full Text]  
• Correll, C. U., Leucht, S., Kane, J. M. (2004). Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. Am. J. Psychiatry 161: 414-425 [Abstract] [Full Text]  
• Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., Sheitman, B. (2004). Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials. Focus 2: 111-121 [Abstract] [Full Text]  
• Andreoli, P. B. d. A., Citero, V. d. A., Mari, J. d. J. (2003). A Systematic Review of Studies of the Cost-Effectiveness of Mental Health Consultation-Liaison Interventions in General Hospitals. Psychosomatics 44: 499-507 [Abstract] [Full Text]  
• Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Campbell, E. C., Caroff, S., Corwin, J., Davis, L., Douyon, R., Dunn, L., Evans, D., Frecska, E., Grabowski, J., Graeber, D., Herz, L., Kwon, K., Lawson, W., Mena, F., Sheikh, J., Smelson, D., Smith-Gamble, V. (2003). Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial. JAMA 290: 2693-2702 [Abstract] [Full Text]  
• Fayek, M., Flowers, C., Signorelli, D., Simpson, G. (2003). Psychopharmacology: Underuse of Evidence-Based Treatments in Psychiatry. Psychiatr. Serv. 54: 1453-1456 [Full Text]  
• MONCRIEFF, J. (2003). Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br. J. Psychiatry 183: 161-166 [Abstract] [Full Text]  
• Davis, J. M., Chen, N., Glick, I. D. (2003). A Meta-analysis of the Efficacy of Second-Generation Antipsychotics. Arch Gen Psychiatry 60: 553-564 [Abstract] [Full Text]  
• DUGGAN, A., WARNER, J., KNAPP, M., KERWIN, R. (2003). Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br. J. Psychiatry 182: 505-508 [Abstract] [Full Text]  
• Thieda, P., Beard, S., Richter, A., Kane, J. (2003). An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia. Psychiatr. Serv. 54: 508-516 [Abstract] [Full Text]  
• Santarlasci, B., Messori, A. (2003). Clinical Trial Response and Dropout Rates with Olanzapine Versus Risperidone. The Annals of Pharmacotherapy 37: 556-563 [Abstract] [Full Text]  
• VOLAVKA, J., CZOBOR, P., LINDENMAYER, J.-P., CITROME, L., McEVOY, J. P., COOPER, T. B., LIEBERMAN, J. A. (2003). Dr. Volavka and Colleagues Reply. Am. J. Psychiatry 160: 592-593 [Full Text]  
• Sernyak, M. J., Leslie, D., Rosenheck, R. (2003). Use of System-Wide Outcomes Monitoring Data to Compare the Effectiveness of Atypical Neuroleptic Medications. Am. J. Psychiatry 160: 310-315 [Abstract] [Full Text]  
• Daumit, G. L., Crum, R. M., Guallar, E., Powe, N. R., Primm, A. B., Steinwachs, D. M., Ford, D. E. (2003). Outpatient Prescriptions for Atypical Antipsychotics for African Americans, Hispanics, and Whites in the United States. Arch Gen Psychiatry 60: 121-128 [Abstract] [Full Text]  
• Leslie, D. L., Rosenheck, R. A. (2002). From Conventional to Atypical Antipsychotics and Back: Dynamic Processes in the Diffusion of New Medications. Am. J. Psychiatry 159: 1534-1540 [Abstract] [Full Text]  
• O'Brien, A., Firn, M. (2002). Clozapine initiation in the community. Psychiatr. Bull. 26: 339-341 [Abstract] [Full Text]  
• Goff, D. C. (2002). A 23-Year-Old Man With Schizophrenia. JAMA 287: 3249-3257 [Full Text]  
• Rosenheck, R. A. (2001). Organizational Process: A Missing Link Between Research and Practice. Psychiatr. Serv. 52: 1607-1612 [Abstract] [Full Text]  
• Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A., Ganguli, R., McMeniman, M., Borenstein, M. (2001). Clozapine and Haloperidol in Moderately Refractory Schizophrenia: A 6-Month Randomized and Double-blind Comparison. Arch Gen Psychiatry 58: 965-972 [Abstract] [Full Text]  
• Druss, B. G., Rohrbaugh, R. M., Levinson, C. M., Rosenheck, R. A. (2001). Integrated Medical Care for Patients With Serious Psychiatric Illness: A Randomized Trial. Arch Gen Psychiatry 58: 861-868 [Abstract] [Full Text]  
• Azorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Pere, J.-J., Giguere, M., Bourdeix, I. (2001). A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia. Am. J. Psychiatry 158: 1305-1313 [Abstract] [Full Text]  
• Sernyak, M. J., Desai, R., Stolar, M., Rosenheck, R. (2001). Impact of Clozapine on Completed Suicide. Am. J. Psychiatry 158: 931-937 [Abstract] [Full Text]  
• Noordsy, D. L., O'Keefe, C., Mueser, K. T., Xie, H. (2001). Six-Month Outcomes for Patients Who Switched to Olanzapine Treatment. Psychiatr. Serv. 52: 501-507 [Abstract] [Full Text]  
• Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., Sheitman, B. (2001). Effectiveness of Second-Generation Antipsychotics in Patients With Treatment-Resistant Schizophrenia: A Review and Meta-Analysis of Randomized Trials. Am. J. Psychiatry 158: 518-526 [Abstract] [Full Text]  
• Harvey, P. D., Keefe, R. S.E. (2001). Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment. Am. J. Psychiatry 158: 176-184 [Abstract] [Full Text]  
• Frankle, W. G., Shera, D., Berger-Hershkowitz, H., Evins, A. E., Connolly, C., Goff, D. C., Henderson, D. C. (2001). Clozapine-Associated Reduction in Arrest Rates of Psychotic Patients With Criminal Histories. Am. J. Psychiatry 158: 270-274 [Abstract] [Full Text]  
• Kirkpatrick, B., Buchanan, R. W., Ross, D. E., Carpenter, W. T. Jr (2001). A Separate Disease Within the Syndrome of Schizophrenia. Arch Gen Psychiatry 58: 165-171 [Abstract] [Full Text]  
• Mossman, D., Lehrer, D. S. (2000). Conventional and Atypical Antipsychotics and the Evolving Standard of Care. Psychiatr. Serv. 51: 1528-1535 [Abstract] [Full Text]  
• Essock, S. M., Frisman, L. K., Covell, N. H., Hargreaves, W. A. (2000). Cost-effectiveness of Clozapine Compared With Conventional Antipsychotic Medication for Patients in State Hospitals. Arch Gen Psychiatry 57: 987-994 [Abstract] [Full Text]  
• Siris, S. G. (2000). Depression in Schizophrenia: Perspective in the Era of "Atypical" Antipsychotic Agents. Am. J. Psychiatry 157: 1379-1389 [Abstract] [Full Text]  
• Sajatovic, M., Bingham, C. R., Garver, D., Ramirez, L. F., Ripper, G., Blow, F., Lehmann, L. S. (2000). An Assessment of Clinical Practice of Clozapine Therapy for Veterans. Psychiatr. Serv. 51: 669-671 [Abstract] [Full Text]  
• Adams, C., Wilson, P., Gilbody, S., Bagnall, A.-M., Lewis, R. (2000). Drug treatments for schizophrenia. Qual Saf Health Care 9: 73-79 [Full Text]  
• Simpson, G. M., Josiassen, R. C., Stanilla, J. K., de Leon, J., Nair, C., Abraham, G., Odom-White, A., Turner, R. M. (1999). Double-Blind Study of Clozapine Dose Response in Chronic Schizophrenia. Am. J. Psychiatry 156: 1744-1750 [Abstract] [Full Text]  
• Wahlbeck, K., Cheine, M., Essali, A., Adams, C. (1999). Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials. Am. J. Psychiatry 156: 990-999 [Abstract] [Full Text]  
• Conley, R. R., Love, R. C., Kelly, D. L., Bartko, J. J. (1999). Rehospitalization Rates of Patients Recently Discharged on a Regimen of Risperidone or Clozapine. Am. J. Psychiatry 156: 863-868 [Abstract] [Full Text]  
• Rosenheck, R., Cramer, J., Allan, E., Erdos, J., Frisman, L. K., Xu, W., Thomas, J., Henderson, W., Charney, D., for the Department of Veterans Affairs Cooperative, (1999). Cost-effectiveness of Clozapine in Patients With High and Low Levels of Hospital Use. Arch Gen Psychiatry 56: 565-572 [Abstract] [Full Text]  
• Soumerai, S. B., Ross-Degnan, D. (1999). Inadequate Prescription-Drug Coverage for Medicare Enrollees -- A Call to Action. NEJM 340: 722-728 [Full Text]  
• Rosenheck, R., Dunn, L., Peszke, M., Cramer, J., Xu, W., Thomas, J., Charney, D., the Department of Veterans Affairs Cooperative Stu, (1999). Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. Am. J. Psychiatry 156: 88-93 [Abstract] [Full Text]  
• Rosenheck, R., Charney, D., Cramer, J. (1999). Clozapine and Hospitalization. Psychiatr. Serv. 50: 114a-115a [Full Text]  
• Reid, W. H., Mason, M., Hogan, T. (1999). Clozapine and Suicides. Psychiatr. Serv. 50: 116a-117a [Full Text]  
• Blieden, N., Flinders, S., Hawkins, K., Reid, M., Alphs, L. D., Arfken, C. L. (1998). Health Status and Health Care Costs for Publicly Funded Patients With Schizophrenia Started on Clozapine. Psychiatr. Serv. 49: 1590-1593 [Abstract] [Full Text]  
• Rosenheck, R., Harkness, L., Johnson, B., Sweeney, C., Buck, N., Deegan, D., Kosten, T. (1998). Intensive Community-Focused Treatment of Veterans With Dual Diagnoses. Am. J. Psychiatry 155: 1429-1433 [Full Text]  
• Jones, P. (1998). Clozapine reduced symptoms and side effects in patients who had refractory schizophrenia. Evid. Based Ment. Health 1: 82-82 [Full Text]  
• Rosenheck, R., Tekell, J., Peters, J., Cramer, J., Fontana, A., Xu, W., Thomas, J., Henderson, W., Charney, D., for the Department of Veterans Affairs Cooperative, (1998). Does Participation in Psychosocial Treatment Augment the Benefit of Clozapine?. Arch Gen Psychiatry 55: 618-625 [Abstract] [Full Text]  
• Ghaemi, S. N., Ziegler, D. M., Peachey, T. J., Goodwin, F. K. (1998). Cost-Effectiveness of Clozapine Therapy for Severe Psychosis. Psychiatr. Serv. 49: 829-831 [Abstract] [Full Text]  
• Birkett, D. P., Rosenheck, R., Charney, D., Cramer, J. (1998). Clozapine Compared with Haloperidol for Refractory Schizophrenia. NEJM 338: 268-268 [Full Text]  
• (1997). Clozapine vs. Haloperidol for Refractory Schizophrenia. JWatch Psychiatry 1997: 8-8 [Full Text]  
• (1997). CLOZAPINE VS. HALOPERIDOL FOR REFRACTORY SCHIZOPHRENIA. JWatch General 1997: 6-6 [Full Text]  
• Keith, S. J. (1997). Pharmacologic Advances in the Treatment of Schizophrenia. NEJM 337: 851-852 [Full Text]